Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1993 Jul;67(7):3917–3922. doi: 10.1128/jvi.67.7.3917-3922.1993

Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses.

M F Bachmann 1, T M Kündig 1, C P Kalberer 1, H Hengartner 1, R M Zinkernagel 1
PMCID: PMC237758  PMID: 8389912

Abstract

The effects of formalin on the infectivity and immunogenicity of vesicular stomatitis virus (VSV) serotype Indiana were investigated. We found that formalin inactivation of VSV prevents infection of Vero cells in a concentration- and time-dependent manner, as shown by fluorometric cell analysis and inhibition of plaque formation. Inactivated VSV failed to induce significant cytotoxic T-lymphocyte responses in vivo or after restimulation in vitro. In contrast, the early immunoglobulin M (IgM) response, which is T help independent in the VSV system, was unaltered, suggesting normal antigenicity for and induction of B cells. However, no switch to IgG occurred, demonstrating failure of induction of T help. If cross-reactive T help was provided by previous infection with a second serotype of VSV (New Jersey), the IgG response was almost completely restored, confirming that the absence of IgG was due to lack of T help. A formalin-treated preparation of glycoprotein of VSV led to a delayed but otherwise normal IgG response, whereas treatment of VSV with UV light or beta-propiolactone reduced IgG titers to the same extent as did formalin. These results suggest that loss of infectivity and the ensuing lack of amplification of viral antigens of formaldehyde-inactivated VSV is the major factor impairing induction of specific T-helper cell responses.

Full text

PDF
3922

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aichele P., Hengartner H., Zinkernagel R. M., Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med. 1990 May 1;171(5):1815–1820. doi: 10.1084/jem.171.5.1815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Binder D., Kündig T. M. Antiviral protection by CD8+ versus CD4+ T cells. CD8+ T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL. J Immunol. 1991 Jun 15;146(12):4301–4307. [PubMed] [Google Scholar]
  3. Charan S., Zinkernagel R. M. Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus. J Immunol. 1986 Apr 15;136(8):3057–3061. [PubMed] [Google Scholar]
  4. Evans D. M., Dunn G., Minor P. D., Schild G. C., Cann A. J., Stanway G., Almond J. W., Currey K., Maizel J. V., Jr Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985 Apr 11;314(6011):548–550. doi: 10.1038/314548a0. [DOI] [PubMed] [Google Scholar]
  5. Germain R. N. Immunology. The ins and outs of antigen processing and presentation. Nature. 1986 Aug 21;322(6081):687–689. doi: 10.1038/322687a0. [DOI] [PubMed] [Google Scholar]
  6. Gobet R., Cerny A., Rüedi E., Hengartner H., Zinkernagel R. M. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp Cell Biol. 1988;56(4):175–180. doi: 10.1159/000163477. [DOI] [PubMed] [Google Scholar]
  7. Horstmann D. M. Control of poliomyelitis: a continuing paradox. J Infect Dis. 1982 Oct;146(4):540–551. doi: 10.1093/infdis/146.4.540. [DOI] [PubMed] [Google Scholar]
  8. Horstmann D. M. Maxwell Finland lecture: viral vaccines and their ways. Rev Infect Dis. 1979 May-Jun;1(3):502–516. doi: 10.1093/clinids/1.3.502. [DOI] [PubMed] [Google Scholar]
  9. Kelley J. M., Emerson S. U., Wagner R. R. The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J Virol. 1972 Dec;10(6):1231–1235. doi: 10.1128/jvi.10.6.1231-1235.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kündig T. M., Castelmur I., Bachmann M. F., Abraham D., Binder D., Hengartner H., Zinkernagel R. M. Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus. J Virol. 1993 Jun;67(6):3680–3683. doi: 10.1128/jvi.67.6.3680-3683.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Le Grand R., Vaslin B., Vogt G., Roques P., Humbert M., Dormont D. AIDS vaccine developments. Nature. 1992 Feb 20;355(6362):684–684. doi: 10.1038/355684a0. [DOI] [PubMed] [Google Scholar]
  12. Lefrancios L., Lyles D. S. The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies. Virology. 1982 Aug;121(1):157–167. [PubMed] [Google Scholar]
  13. Lefrancois L., Lyles D. S. The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes. Virology. 1982 Aug;121(1):168–174. doi: 10.1016/0042-6822(82)90126-x. [DOI] [PubMed] [Google Scholar]
  14. Leist T. P., Cobbold S. P., Waldmann H., Aguet M., Zinkernagel R. M. Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol. 1987 Apr 1;138(7):2278–2281. [PubMed] [Google Scholar]
  15. Mackett M., Yilma T., Rose J. K., Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science. 1985 Jan 25;227(4685):433–435. doi: 10.1126/science.2981435. [DOI] [PubMed] [Google Scholar]
  16. McLAREN L. C., HOLLAND J. J., SYVERTON J. T. The mammalian cell-virus relationship. I. Attachment of poliovirus to cultivated cells of primate and non-primate origin. J Exp Med. 1959 May 1;109(5):475–485. doi: 10.1084/jem.109.5.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Meyer H. M., Jr, Hopps H. E., Parkman P. D., Ennis F. A. Review of existing vaccines for influenza. Am J Clin Pathol. 1978 Jul;70(1 Suppl):146–152. [PubMed] [Google Scholar]
  18. Morrison L. A., Lukacher A. E., Braciale V. L., Fan D. P., Braciale T. J. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med. 1986 Apr 1;163(4):903–921. doi: 10.1084/jem.163.4.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nkowane B. M., Wassilak S. G., Orenstein W. A., Bart K. J., Schonberger L. B., Hinman A. R., Kew O. M. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987 Mar 13;257(10):1335–1340. [PubMed] [Google Scholar]
  20. Osler A. G. Immunology of reaginic allergy: in vitro studies. Clin Exp Immunol. 1970 Jan;6(1):13–23. [PMC free article] [PubMed] [Google Scholar]
  21. Puddington L., Bevan M. J., Rose J. K., Lefrançois L. N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells. J Virol. 1986 Nov;60(2):708–717. doi: 10.1128/jvi.60.2.708-717.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Roost H. P., Charan S., Zinkernagel R. M. Analysis of the kinetics of antiviral memory T help in vivo: characterization of short-lived cross-reactive T help. Eur J Immunol. 1990 Dec;20(12):2547–2554. doi: 10.1002/eji.1830201204. [DOI] [PubMed] [Google Scholar]
  23. Roscoe D. M., Ishikawa K., Lyles D. S. Role of de novo protein synthesis in target cells recognized by cytotoxic T lymphocytes specific for vesicular stomatitis virus. J Virol. 1991 Dec;65(12):6856–6861. doi: 10.1128/jvi.65.12.6856-6861.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosenthal K. L., Zinkernagel R. M. Cross-reactive cytotoxic T cells to serologically distinct vesicular stomatitis virus. J Immunol. 1980 May;124(5):2301–2308. [PubMed] [Google Scholar]
  25. Sabin A. B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985 Mar;151(3):420–436. doi: 10.1093/infdis/151.3.420. [DOI] [PubMed] [Google Scholar]
  26. Salk J., Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science. 1977 Mar 4;195(4281):834–847. doi: 10.1126/science.320661. [DOI] [PubMed] [Google Scholar]
  27. Sarobe P., Lasarte J. J., Golvano J., Gullón A., Civeira M. P., Prieto J., Borrás-Cuesta F. Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable T helper peptide. Eur J Immunol. 1991 Jun;21(6):1555–1558. doi: 10.1002/eji.1830210633. [DOI] [PubMed] [Google Scholar]
  28. VINCENT J., BELANGER L. F., MIGICOVSKY B. B. [Mineralization in the rachitic bone. Alpharadiographic and microradiographic study]. Exp Cell Res. 1962 Feb;26:168–174. doi: 10.1016/0014-4827(62)90212-4. [DOI] [PubMed] [Google Scholar]
  29. Van Bleek G. M., Nathenson S. G. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature. 1990 Nov 15;348(6298):213–216. doi: 10.1038/348213a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES